Targeting EZH2 to improve treatment for prostate cancer
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer
This study is looking at new ways to target a protein called EZH2 that helps prostate cancer grow, with the hope of creating better treatments for patients who aren't responding well to current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10973062 on NIH RePORTER |
What this research studies
This research focuses on developing new protein degraders that specifically target the non-enzymatic functions of EZH2, a protein that plays a critical role in the progression of prostate cancer. By understanding how EZH2 contributes to cancer growth and resistance to treatment, the research aims to create innovative therapies that can effectively degrade EZH2 proteins. This approach could potentially overcome the limitations of current treatments that have not been successful in all cases of castration-resistant prostate cancer (CRPC). Patients may benefit from new treatment options that could improve survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, especially those who have developed resistance to standard treatments.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, particularly for patients with castration-resistant forms of the disease.
How similar studies have performed: While targeting EZH2 has been explored in other studies, this specific approach using protein degraders is relatively novel and has not been extensively tested.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yu, Jindan — Emory University
- Study coordinator: Yu, Jindan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.